Full Answer
2021 ICD-10-CM Codes F12*: Cannabis related disorders. ICD-10-CM Codes. ›. F01-F99 Mental, Behavioral and Neurodevelopmental disorders. ›. F10-F19 Mental and behavioral disorders due to psychoactive substance use. ›.
R63.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM R63.0 became effective on October 1, 2018. This is the American ICD-10-CM version of R63.0 - other international versions of ICD-10 R63.0 may differ.
R11.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM R11.2 became effective on October 1, 2018. This is the American ICD-10-CM version of R11.2 - other international versions of ICD-10 R11.2 may differ.
2018/2019 ICD-10-CM Diagnosis Code M62.82. Rhabdomyolysis. M62.82 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM M62.82 became effective on October 1, 2018.
ICD-10-CM Code for Anorexia R63. 0.
ICD-10 Code for Other long term (current) drug therapy- Z79. 899- Codify by AAPC.
R63. 0 - Anorexia | ICD-10-CM.
ICD-10-CM Codes that Support Medical Necessity For monitoring of patient compliance in a drug treatment program, use diagnosis code Z03. 89 as the primary diagnosis and the specific drug dependence diagnosis as the secondary diagnosis.
ICD-10 Code for Encounter for issue of repeat prescription- Z76. 0- Codify by AAPC.
Z51. 81 Encounter for therapeutic drug level monitoring - ICD-10-CM Diagnosis Codes.
9: Fever, unspecified.
T73.0XXAT73. 0XXA is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM T73.
Y93.9ICD-10 code Y93. 9 for Activity, unspecified is a medical classification as listed by WHO under the range - External causes of morbidity .
CPT code 80306: Drug test(s), presumptive, any number of drug classes, qualitative, any number of devices or procedures, (e.g., immunoassay) read by instrument assisted direct optical observation (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service.
CPT® 80307, Under Presumptive Drug Class Screening Procedures. The Current Procedural Terminology (CPT®) code 80307 as maintained by American Medical Association, is a medical procedural code under the range - Presumptive Drug Class Screening Procedures.
The ICD-10 section that covers long-term drug therapy is Z79, with many subsections and specific diagnosis codes. Because Plaquenil does not have its own specific category, clinicians should use Z79. 899—Other Long Term (Current) Drug Therapy.
Dietary counseling and surveillanceICD-10 code Z71. 3 for Dietary counseling and surveillance is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Other symptoms and signs concerning food and fluid intake The 2022 edition of ICD-10-CM R63. 8 became effective on October 1, 2021. This is the American ICD-10-CM version of R63.
ICD-9 Code Transition: 780.79 Code R53. 83 is the diagnosis code used for Other Fatigue. It is a condition marked by drowsiness and an unusual lack of energy and mental alertness. It can be caused by many things, including illness, injury, or drugs.
Code R13. 10 is the diagnosis code used for Dysphagia, Unspecified. It is a disorder characterized by difficulty in swallowing. It may be observed in patients with stroke, motor neuron disorders, cancer of the throat or mouth, head and neck injuries, Parkinson's disease, and multiple sclerosis.
Signs and symptoms of Dronabinol overdosage include drowsiness, euphoria, heightened sensory awareness, altered time perception, reddened conjunctiva, dry mouth, tachycardia, memory impairment, depersonalization, mood alteration, urinary retention, reduced bowel motility, decreased motor coordination, lethargy, slurred speech, and postural hypotension. Patients may also experience panic reactions if they have a prior history of nervousness or anxiety, and seizures may occur in patients with existing seizure disorders.
Dronabinol, the active ingredient in Dronabinol capsules, USP, is synthetic delta-9-tetrahydrocannabinol (delta-9-THC). Dronabinol is a light yellow resinous oil that is sticky at room temperature and hardens upon refrigeration. Dronabinol is insoluble in water and is formulated in sesame oil.
Dronabinol also demonstrates reversible effects on appetite, mood, cognition, memory, and perception. These phenomena appear to be dose-related, increasing in frequency with higher dosages, and subject to great inter-patient variability. After oral administration, Dronabinol has an onset of action of approximately 0.5 to 1 hours and peak effect at 2 to 4 hours. Duration of action for psychoactive effects is 4 to 6 hours, but the appetite stimulant effect of Dronabinol may continue for 24 hours or longer after administration.
Dronabinol is an orally active cannabinoid which has complex effects on the CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of Dronabinol.
These subjects developed tolerance to the cardiovascular and subjective adverse CNS effects of Dronabinol within 12 days of treatment initiation. Tachyphylaxis and tolerance do not appear to develop to the appetite stimulant effect of Dronabinol capsules.
Dronabinol is primarily metabolized by CYP2C9 and CYP3A4 enzymes based on published in vitro studies. Inhibitors of these enzymes may increase, while inducers may decrease, the systemic exposure of Dronabinol and/or its active metabolite resulting in an increase in Dronabinol-related adverse reactions or loss of efficacy of Dronabinol capsules.
Cognitive Adverse Reactions. Use of Dronabinol capsules has been associated with cognitive impairment and altered mental state. Reduce the dose of Dronabinol capsules or discontinue use of Dronabinol capsules if signs or symptoms of cognitive impairment develop.